Ever Supreme Bio Technology announced on 3 December its consolidated revenue of $60.51 million for December 2022, an increase of 15% year-on-year and a record high for the 10th consecutive month of positive revenue growth. Mr. Wen-liang Huang, President of Ever Supreme, said that with the diversified cell therapy products, he is confident that the company will continue to grow steadily this year.

The company's cell therapy business is focused on two main areas. Under a regulation regarding regenerative medicine, the Ministry of Health and Welfare has approved 37 cases of immunotherapy for cancer treatment, and the company has partnered with 15 hospitals to provide six cell therapy products to treat patients.

Ever Supreme said that the company has received positive feedback from doctors and patients on its cell therapy, with more than 500 patients using its developed cells so far and the next patients scheduled to receive treatment by the third quarter of this year.

In terms of new pipeline, the three major indications for allogeneic umbilical cord mesenchymal stem cells (UMSC01), namely acute myocardial infarction, cerebral stroke and multiple sclerosis, have entered the human clinical trial stage. Phase I clinical trial for acute myocardial infarction, the fastest progressing, has been completed and is currently in Phase II clinical submission to the US Food and Drug Administration (FDA); the second indication, stroke, is also in Phase I clinical trial.

According to Ever Supreme, the third indication for UMSC01, multiple sclerosis, has recently received approval from the TFDA to initiate Phase I/IIa clinical trials in both Taiwan and the US, and the Phase I clinical trial is expected to commence in the second quarter of this year with a caseload of six. Once the Phase I clinical trial for MS is completed and the safety committee has given its approval, it can proceed directly to the Phase IIa clinical trial, which is expected to shorten the development period of the new drug by 1-2 years.

The government is pushing for the introduction of the laws on regenerative medicine, which will potentially allow cellular therapy to be licensed with conditions for specific diseases, subject only to the completion of Phase II clinical trials," said Ever Supreme. It is expected that all three major indications of UMSC01 will be legally eligible, thus shortening the drug launch time.

Multiple sclerosis, a neurodegenerative disease affecting the brain and spinal cord, is a chronic disease that causes disabling conditions, the company added.